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Development of dendritic cells (DCs) commences
in the bone marrow, from where pre-DCs migrate
to peripheral organs to differentiate into mature
DCs in situ. However, the factors that regulate
organ-specific differentiation to give rise to tissue-
specific DC subsets remain unclear. Here we show
that the Ras-PI3Kg-Akt-mTOR signaling axis acted
downstream of FLT3L signaling and was required
for development of lung CD103+ DCs and, to a
smaller extent, for lung CD11b+ DCs, but not related
DC populations in other non-lymphoid organs.
Furthermore, we show that in lymphoid organs
such as the spleen, DCs depended on a similar
signaling network to respond to FLT3 ligand with
overlapping and partially redundant roles for ki-
nases PI3Kg and PI3Kd. Thus we identified PI3Kg
as an essential organ-specific regulator of lung DC
development and discovered a signaling network
regulating tissue-specific DC development medi-
ated by FLT3.
INTRODUCTION
Dendritic cells (DCs) are specialized antigen-presenting cells
particularly geared to sense harmful perturbations in the cellular
environment and initiate antigen-specific immune responses.
They are also important for maintaining tolerance to self-anti-
gens (Merad et al., 2013; Steinman and Nussenzweig, 2002).
DCs form a distinct hematopoietic lineage (Schraml et al.,
2013) and continuously develop from the bone marrow (BM)
through committed precursor stages (Merad et al., 2013).
Pre-DCs, the immediate DC precursors, seed peripheral organs
and differentiate in situ into mature DCs (Waskow et al.,
2008). The DC compartment in the periphery consists of
different cell subsets that are associated with exerting different
functions (Guilliams et al., 2013). In non-lymphoid tissues
(NLTs), conventional DC subpopulations can be distinguished
by surface expression of CD103 (also known as integrin aE)674 Immunity 43, 674–689, October 20, 2015 ª2015 Elsevier Inc.and CD11b (integrin aM) (Ginhoux et al., 2009), although
recently it was shown that CD11b+ DCs are actually a hetero-
geneous population, consisting of conventional DCs as well
as monocyte-derived cells (Plantinga et al., 2013; Schlitzer
et al., 2013). CD103+ DCs in NLTs as well as CD8a+ DCs in
lymphoid tissues form an independent DC sub-lineage, criti-
cally dependent on the transcription factors (TFs) BATF3, ID2,
and IRF8 for their development (Hashimoto et al., 2011). By
contrast, development of conventional CD11b+ DCs in NLTs
is dependent on the TF IRF4 in NLTs (Schlitzer et al., 2013)
as well as IRF2, IKAROS, RELB, NOTCH2, and RBP/J for the
corresponding endothelial cell selective adhesion molecule
(ESAM)hiCD4+ DCs in the spleen (Hashimoto et al., 2011;
Merad et al., 2013).
Fms-like tyrosine kinase 3 ligand receptor (FLT3) is a critical
regulator of DC development and has been implicated in
control of DC differentiation at various stages (Merad et al.,
2013) including regulation of the number of DC precursors
in the BM (Kingston et al., 2009) and inducing proliferation
and differentiation of pre-DCs in the periphery (Waskow
et al., 2008). Although important for the development of all
conventional DC subsets in peripheral organs, studies have
shown that FLT3 dependence differs depending on the
DC subset (Ginhoux et al., 2009; Schlitzer et al., 2013).
CD103+ DCs in NLTs are more critically dependent on FLT3
signaling than both CD11b+ DCs in the same location and
all DC subsets in lymphoid tissues (LTs) (Schlitzer et al.,
2013). Furthermore, the source of FLT3 ligand (FLT3L) has
also been shown to differ between organs (Saito et al., 2013),
suggesting an organ-specific regulation of FLT3-mediated DC
homeostasis. Downstream of FLT3, mammalian target of rapa-
mycin (mTOR) signaling (Sathaliyawala et al., 2010) and TF
STAT3 activation (Laouar et al., 2003) have been shown to be
essential signaling events after receptor activation. How this
process is regulated in different DC subsets and what further
signaling components might regulate FLT3-dependent den-
dritic cell homeostasis in an organ-specific manner remain
largely unclear.
Phosphoinositide 3-kinases (PI3K) are important signal trans-
duction proteins that regulate many key intracellular processes
including transcription, cytoskeletal dynamics, and membrane
trafficking. The p110g catalytic subunit is a member of the class
Ib PI3-kinases that forms heterodimers with subunits p101 or
AB
Figure 1. p110g Is Essential for Lung DC Development but Dispensable for DCs in Other Non-Lymphoid Organs
Non-lymphoid organs of naive WT, Pik3cg /, and Pik3cgKD/KD mice were analyzed for their DC subsets by flow cytometry. Shown are representative FACS dot
plots (A) of organs indicated as well as quantification of FACS data (B) of groups of mice. Gating strategies are shown in Figure S1A. In brief, conventional DCs in
(legend continued on next page)
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p84 and is commonly associated with signaling downstream of
G protein coupled receptors (Okkenhaug, 2013) as well as re-
ceptor tyrosine kinases (Schmid et al., 2011). It has been shown
to have both protein kinase and lipid kinase capacity as well as
kinase-independent functions (Patrucco et al., 2004). The
p110g subunit has been suggested to play a prominent role in
immunity and inflammation, in particular by regulating migration
of multiple cell types such as neutrophils and macrophages to
the site of inflammation (Hirsch et al., 2000; Li et al., 2000).
Furthermore, it has been found to have a minor role in lympho-
cyte development (Beer-Hammer et al., 2010; Sasaki et al.,
2000), as well as T cell proliferation (Ladygina et al., 2013). More-
over, p110g is implicated in multiple human diseases such as
atherosclerosis (Zotes et al., 2013) and is thus seen as a prom-
ising therapeutic target in many inflammatory disorders (Costa
et al., 2011).
Here we describe that FLT3 signaling in lung DCs, as opposed
to other organs, was critically dependent on the signal transduc-
tion molecule p110g. We show that the kinase activity of p110g
was essential for differentiation of DC precursors in the lung,
in particular for CD103+ DCs, while being largely dispensable
for DC development in other tissues. We further determine
that the requirement of signaling factors such PI3Ks, Akt, and
mTOR downstream of FLT3 for DC development were strongly
tissue and subset dependent, revealing a signaling network
that confers a layer of tissue specificity to the ubiquitous cytokine
FLT3L.
RESULTS
PI3Kg Kinase Activity Regulates DC Homeostasis in the
Lung
To determine the role of p110g in DC development in the steady
state and discern the relative contribution of its kinase-depen-
dent and kinase-independent functions, we took advantage
of two genetically modified mouse strains. We used p110g ki-
nase-dead animals (Pik3cgKD/KD), which are homozygous for
an inactivating mutation of the kinase domain of p110g but
retain normal protein expression, to study kinase-dependent
functions. In addition we also used global p110g-deficient
mice to evaluate the impact of the complete lack of the protein
on DC homeostasis. Examining the composition of the DC
compartment in NLTs (Figure S1A), we observed a very pro-
nounced reduction the total number of CD103+ DCs and of
CD11b+ conventional DCs to a lesser degree in the lung in
both Pik3cgKD/KD and Pik3cg/ mice (Figures 1A and 1B).
CD103+ DCs were almost completely absent in Pik3cgKD/KD
mice. By contrast, lung plasmacytoid DCs (pDCs) as well as
monocyte-derived DCs (moDCs) were unaffected by the loss
of p110g function. Conversely, DC populations in the lamina
propria of the small intestine (SI LP) were present at wild-type
(WT) frequencies and total numbers in Pik3cgKD/KD and
p110g-deficient animals (Figures 1A and 1B). Similarly, DC pop-the lung were pregated on CD45+CD11c+Siglec-FMHCIIhi. Conventional DC
MHCIIhi and in the skin as CD45+MHCIIhiCD64SIRPa. pDCs in the lung we
PDCA-1hiCD11cint cells. moDCs in the lungs were identified as CD45+SSCloSiglec
Values show means ± SEM of four to six mice per group. Shown are representa
Student’s t test (unpaired) was used: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0
676 Immunity 43, 674–689, October 20, 2015 ª2015 Elsevier Inc.ulations in the liver and kidney were comparable to WT (Figures
1A and 1B). In the skin, CD207+SIRPa conventional DCs
(cDCs), also termed XCR1+ DCs by Malissen et al. (2014),
were also present at WT numbers (Figures 1A and 1B). No
reduction was observed in the number of Langerhans cells
(LCs) (Figures 1A and 1B). In general, pDC and moDC popula-
tions were present at normal numbers in all examined NLTs in
the steady state (Figures 1A, 1B, and S1B). Overall, these re-
sults suggest a crucial role for p110g in the regulation of DC ho-
meostasis in the lung, in particular for cells of the CD103+ DC
subset.
p110g Partially Regulates DC Homeostasis in Lymphoid
Tissues
To gain further understanding about the role of p110g in DC
development, we also characterized the DC compartment in pri-
mary and secondary LTs. In the mediastinal lung draining lymph
node, CD103+ DCs numbers and frequencies were significantly
reduced in both Pik3cg/ and Pik3cgKD/KD mice, mirroring the
strong reduction observed in the lungs of these mice (Figures
2A and 2B). In contrast, in the mesenteric and skin draining
lymph nodes (dLNs) as well as in the Peyer’s patches of the small
intestine, no significant differences could be found in themakeup
of the migratory DC compartment (Figures 2A and 2B). In the
spleen, CD8+ DCs, which are also BATF3 dependent and are
thought to be part of the same lineage as CD103+ DCs, were
moderately reduced in both Pik3cg/ and Pik3cgKD/KD mice
(Figures 2A and 2B) and a similar phenotype was observed for
CD8+ resident DCs in dLNs (data not shown). By contrast,
splenic CD4+ DCs were reduced in both p110g-deficient and
Pik3cgKD/KD animals (Figures 2A and 2B). A moderate reduction
in all DC subsets could be observed in the thymus in accordance
with a general reduction in thymocytes (Figures 2A and 2B), as
previously described (Hirsch et al., 2000). Taken together, these
results confirmed the observations made in the NLTs that p110g
regulates the make up of the DC compartment in an organ-spe-
cific manner.
p110g Is Cell Intrinsically Required for DC Development
in the Lung
To determine whether p110gwas intrinsically required for devel-
opment of DCs in peripheral tissues, we generated mixed
bone marrow chimeras. In the lung, both CD11b+ DCs and
CD103+ DCs, in particular, were critically dependent on intrinsic
p110g kinase function (Figure 3A); Pik3cgKD/KD-derived cells had
a severe competitive disadvantage. In line with data from
Pik3cgKD/KD mice, lung pDCs of Pik3cgKD/KD origin also had no
developmental disadvantage in the mixed chimera situation
(Figure 3A). Furthermore, CD103+ and CD11b+ DC subsets in
the liver, skin, and kidney, as well as the DC subpopulations
in the SI LP, were present at normal ratios in cells derived
from Pik3cgKD/KD bone marrow (Figures 3A–3C). Similarly,
splenic CD8+ DCs and CD4+ DCs with a defective p110g kinases in the liver, kidney, and small intestine were pregated as CD45+CD11c+
re pregated as CD45+SSCloCD11bSiglec-FCD64 and then identified as
-FCD11b+CD64+. Langerhans cells were identified as CD207+SIRPa+CD64.
tive results of two to four experiments. SI LP, small intestinal lamina propria.
.0001. See also Figure S1.
AB
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activity competed comparably well with WT counterparts in
mixed chimeras (Figure 3C). Blood neutrophils were repre-
sented equally and served as a reconstitution control (Figure 3C).
To address the more pronounced defect in splenic CD4+ DCs
in the Pik3cg/ animals as opposed to the Pik3cgKD/KD strain,
we generated mixed bone marrow chimeras with Pik3cg/
bone marrow. We found that Pik3cg/ cells had a severe defi-
ciency in CD4+ DC development (Figure 3D). In addition, we
could confirm the requirement for p110g on lung DCs as shown
in Figure 3C.
Summing up, these results confirm an essential and intrinsic
role for p110g kinase function in development of lung DCs as
well as a role for the non-kinase part of p110g in the generation
of splenic CD4+ DCs.
p110g-Dependent DC Subsets Express High Levels of
p110g and Its Function Is Dosage Dependent
To assess whether dependence on p110g for development of
particular DC subsets can be correlated with expression levels,
we compared the mRNA levels of Pik3cg in DC subpopulations
in LTs and NLTs using the Immgen database (Heng et al.,
2008). Highest Pik3cg expression levels were found in lung
CD103+ DCs as well as splenic CD4+ DCs in the spleen (Fig-
ure 4A). CD11b+ DCs in the lung also expressed high amounts
of Pik3cg, while related cells from that lineage in other NLTs
suchas liverandkidneyexpressed lowermRNAlevels (Figure4A).
The high Pik3cg expression levels of both lung DC subsets as
well as splenic CD4+ DCs were confirmed by qPCR (Figure S2A)
and at the protein level by intracellular flow cytometric staining
(Figures 4B and 4C) where B cells were shown to illustrate the
higher expression level of p110g in DCs in general. To evaluate
whether the levels of p110g could influence DC development,
particularly in high expressing CD103+ lung DCs, we analyzed
the DC subset composition in heterozygous Pik3cgKD/KD mice.
Pik3cgKD/+ mice showed an intermediate phenotype in the lung
for CD103+DCs, butCD11b+DCswere present at numbers com-
parable to WT animals (Figure 4D). This suggested a dosage-
dependent function of p110g at least in lung CD103+ DCs.
To further elucidate the role of p110g in early DC development,
we characterized theDC subset composition in lungs of perinatal
mice. One day after birth, WT mice had clearly detectable pul-
monary DC populations. Flow cytometric analysis of lungs of
these young mice showed that p110g is essential for CD103+
DC development because Pik3cgKD/KD mice lacked these cells
completely at this time point (Figures 4E and 4F). However, pul-
monary CD11b+ DCs were unaffected by the loss of p110g (Fig-
ures 4E and 4F) at this stage of development. Similarly, splenic
DC subsets were also readily detectable at 1 day after birth
and the absence of p110g kinase function had no consequence
for their development (Figures 4E and 4F).
In order to better understand the role of p110g in DC develop-
ment, we sought to characterize DC precursors in the BM as wellFigure 2. p110g Kinase Function Is Required for Splenic DC Developm
Lymphoid organs of naiveWT, Pik3cg/, and Pik3cgKD/KDmice were analyzed for
draining, skin draining, andmesenteric lymph nodes, Peyer’s patches, and spleen
of four to six mice per group. cDCs were pregated as CD45+CD11c+MHCIIhi cells.
as PDCA-1hiCD11cint cells. Shown are representative results of two to four experi
****p < 0.0001.
678 Immunity 43, 674–689, October 20, 2015 ª2015 Elsevier Inc.as in peripheral tissues in Pik3cgKD/KD mice. In the bone marrow,
committed precursors (macrophage-dendritic cell precursors or
MDPs) give rise to both DCs andmonocytes, which further differ-
entiate into common dendritic cell precursors (CDPs) and then
pre-DCs, which are the immediate DC precursors. Flow cyto-
metric analysis of bone marrow from Pik3cgKD/KD mice revealed
that MDPs, CDPs, and pre-DCs were present at normal fre-
quencies (Figures 4G, 4H, and S2B–S2D). Similarly, in the blood
as well as the spleen and liver of Pik3cgKD/KD animals, pre-cDCs
were present at comparable numbers to WT mice (Figure 4I). In
the lung, however, the number of pre-DCs was considerably
reduced in Pik3cgKD/KD mice in the steady state (Figure 4I). To
confirm a cell-intrinsic role of p110g in regulating the biology of
DC precursors, we also examined these cells in the mixed
bone marrow chimera situation. No competitive advantage
was observed at the level of p110g-sufficient cells in the bone
marrow (Figure 4J). As expected, lung pre-DCs of Pik3cgKD/KD
origin are present at lower frequencies compared to their WT
counterparts (Figure 4J). Taken together, these results suggest
an important role of p110g in the development of lung DCs at
the level of the lung-resident pre-DCs.
FLT3 Signaling in Pulmonary DCs Critically Relies on
p110g
FLT3L is an essential cytokine for DC development and it regu-
lates differentiation and proliferation of pre-cDCs in situ (Was-
kow et al., 2008). Administration of FLT3L can thus be used to
expand DCs in peripheral tissues. To evaluate a possible link
between p110g and FLT3 signaling, we administered FLT3L to
Pik3cgKD/KD and Pik3cg/ mice. After 8 days of FLT3L treat-
ment, the number CD103+ DCs and CD11b+ DCs in the lungs
of WT mice expanded by about 2-fold versus untreated mice
(Figure 5A), and this expansion was completely abrogated in
Pik3cg/ and Pik3cgKD/KD animals (Figure 5A). In contrast, the
number of pDCs increased comparably (i.e., 6-fold) in the lungs
of WT, Pik3cg/, and Pik3cgKD/KD mice (Figure 5A). Expansion
of CD103+ and CD11b+ DCs in the liver as well as CD8+ DCs in
the spleen was reduced but not absent in p110g-kinase-defi-
cient animals (Figures 5A and 5B). However, expansion of
CD4+ DCs in the spleen was completely abrogated in global
p110g knockout animals (Figure 5A). To exclude possible indirect
effects that could explain the lack of FLT3L-mediated expansion
of lung CD103+ DCs in Pik3cgKD/KD mice, we generated mixed
BM chimeric mice, where irradiated WT mice received either
WT and Batf3/ or Pik3cgKD/KD and Batf3/ BM at a ratio of
1:4. This generated a situation in the Pik3cgKD/KDBatf3/mixed
chimera where 80% of cells carried a wild-type copy of Pik3cg
(derived from the Batf3/ BM) but all CD103+ DCs carried the
Pik3cgKD/KD mutation, because the Batf3/ BM cells cannot
develop into this lineage. After complete reconstitution, mice
were treated with FLT3L and DC subsets were subsequently
analyzed. Pulmonary CD103+ DCs in mice, which had receivedent
their DC subsets. Shown are representative FACS dot plots (A) of thymus, lung
. Quantification of FACS data (B) of groups of mice. Values showmeans ± SEM
pDCs were pregated as CD45+SSCloCD11b for the spleen and then identified
ments. Student’s t test (unpaired) was used: *p < 0.05, **p < 0.01, ***p < 0.001,
AB
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WT BM, expanded significantly, although to a slightly lower de-
gree than CD11b+ DCs (Figure 5C). The expansion of lung
CD103+ DCs was absent in mice containing a Pik3cgKD/KD muta-
tion selectively in BATF3-dependent DCs. As expected, p110g-
competent lung CD11b+ DCs in Batf3/Pik3cgKD/KD mixed BM
chimeras expanded after FLT3L treatment, albeit to a somewhat
lower degree than WT DCs. Splenic CD8+ DCs as well as liver
CD103+ DCs expanded to a similar degree between WT and
Pik3cgKD/KD recipients, thus suggesting a lung-specific intrinsic
role for p110g kinase function in FLT3 signaling (Figure 5C). To
examine further the connection between FLT3 and p110g, we
sought to measure FLT3 expression on the remaining lung DCs
in Pik3cgKD/KD animals. In WT animals, it is evident that cell sur-
face expression of FLT3 is highest on conventional CD103+ and
CD11b+ DCs and lower on moDCs (Figure 5D) as has been re-
ported previously (Schlitzer et al., 2013). In the remaining cDCs
in Pik3cgKD/KD mice, the amount of FLT3 surface expression
was comparable to WT, although slightly reduced (Figure 5E).
To more comprehensively understand the role of FLT3 in DC
development in general, we sought to characterize FLT3-defi-
cient as well as heterozygous animals to evaluate possible
dosage effects of FLT3 signaling. As expected, Flt3/ animals
had a strong defect in lung and liver DCs, in particular in the
CD103+ DC subset (Figure 5F). Interestingly, mice heterozygous
for FLT3 also exhibited a reduction in the number of lung-resident
CD103+ DCs (Figure 5F), as observed by comparing WT and
Pik3cgKD/+ mice. Consistently, DCs derived from Flt3+/ animals
had lower surface expression of this receptor (Figure 5G)
compared to WT mice. Overall, these data suggested that FLT3
signaling isdosageandp110gdependent in lungDCs,while there
is an additional non-p110g-dependent signaling pathway down-
stream of FLT3 in DCs located in other organs such as the liver.
p110g Mediates Proliferation of DCs in the Lung but Is
Dispensable for Their In Situ Survival
To address the underlying mechanism by which FLT3 through
p110g exerts its function on DC homeostasis, we examined a
possible regulation of survival of mature DCs as well as pre-
DCs in peripheral organs in situ. For this purpose we analyzed
the proportion of apoptotic cells in naive organs at the steady
state. No increase in the frequency of apoptotic cells was
observed in the remaining DCs in the lungs of Pik3cgKD/KD
mice (Figure S3A). The same was true for pre-DCs in the lung
as well as for DCs in the spleen of Pik3cgKD/KDmice (Figure S3A).
Because FLT3L has also been implicated to play a role in driving
both differentiation as well as proliferation of pre-DCs and
mature DCs in vivo, we sought to evaluate DC proliferation at
steady state in the absence of p110g signaling. By examining
the proportion of cells expressing Ki-67, a commonly used pro-Figure 3. p110g Is Intrinsically Required for Lung and Splenic CD4+ DC
(A–C)WTmice were lethally irradiated and reconstituted with a mixture of either W
1:1 ratio. After 10 weeks reconstitution, organs of naive recipient mice were analy
well as a summary of the FACS data (mean ± SEM), where the frequency of CD45.
liver, small intestine, and skin (B), and in the blood, spleen, and thymus (C).
(D) WT mice were irradiated as above and reconstituted with a mixture of either W
1:1 ratio. After 10 weeks, organs of naive recipient mice were analyzed for DC su
summary of the FACS data (mean ± SEM), where the frequency of CD45.2+ cells
Shown are representative results from two to four experiments. Student’s t test
680 Immunity 43, 674–689, October 20, 2015 ª2015 Elsevier Inc.liferation marker, we found that the remaining DCs in the lungs of
Pik3cgKD/KD mice were proliferating at lower frequencies than
WT cells (Figures S3B and S3C). To confirm the role of p110g
in DC proliferation at steady state, we examined BrdU incorpora-
tion in lung DCs after a single short pulse of BrdU. In Pik3cgKD/KD
mice, both the low number of remaining CD11b+ as well as
CD103+ DCs had a decreased frequency of BrdU incorporation
compared to WT controls (Figures S3D and S3E). Furthermore,
treatment of WT animals with Wortmannin, a PI3K inhibitor,
and subsequent analysis of incorporation of EdU, another thymi-
dine analog, showed that lung DCs strongly depended on PI3K
for proliferation at steady state, whereas PI3K was dispensable
for liver DCs (Figures S3F and S3G). Similarly, Wortmannin treat-
ment reduced the frequency of lung-resident pre-DC EdU incor-
poration but not that of precursor populations in the spleen,
blood, and BM. Thus, functional p110g is exclusively required
for proliferation of mature DCs and pre-DCs in the lung in situ
but dispensable for their survival.
PI3Ks and Akt Control DC Development in an Organ-
Specific Manner
In order to better understand the organ-specific regulation of
FLT3 signaling in DCs, we sought to dissect the signaling path-
ways required for FLT3L-mediated DC development. For this
purpose we injected FLT3L as well as the pan-PI3K inhibitor
Wortmannin daily in similar set up as described in Figure 5.Wort-
mannin treatment strongly reduced lung CD103+ as well as
CD11b+ DC numbers at steady state and also blocked FLT3L-
mediated expansion of these cells (Figure 6A), as well as of
lung-resident pre-DCs (Figure S3A). By contrast, DCs in the liver
and the SI LP were largely unaffected by Wortmannin treatment
in the steady-state and also expanded significantly despite PI3K
inhibition (Figure 6A). In the spleen, CD8+ DCs homeostasis was
unaffected but their expansion was strongly inhibited by Wort-
mannin (Figure 6A). CD4+ DCs, on the other hand, were slightly
decreased by PI3K inhibition in the steady state and their expan-
sion was also blocked by this inhibitor (Figure 6A). Furthermore,
pDCs in the spleen but not in the lungs depended on PI3K for
their expansion and homeostasis (Figures 6A and S3A). Pre-
DCs in the blood and spleen and DC precursors in the bone
marrow were not significantly affected by blocking PI3K
signaling (Figure S3A). To further discern the PI3K subunit con-
trolling FLT3L responsiveness, in splenic DCs in particular, we
treated mice with IC87114, an inhibitor of the p110d subunit.
The PI3K p110d subunit was also significantly expressed by
most DC subsets in different organs (Figure S4B). We used
marginal zone B cells as a control, which are strongly p110d
dependent (Figure S4C). Inhibition of p110d blocked FLT3L-
induced expansion of splenic DCs, particularly the CD8+ subsetDevelopment
T(CD45.1):WT(CD45.2) or WT(CD45.1):Pik3cgKD/KD (CD45.2) bone marrow at a
zed for DC subsets. Shown are representative FACS dot plots of recipients as
2+ cells is shown for the respective DC subsets in the lung and kidney (A), in the
T(CD45.1):WT(CD45.2) or WT(CD45.1): Pik3cg/ (CD45.2) bone marrow at a
bsets. Shown are representative FACS dot plots of recipient mice as well as a
was normalized to the frequency of B cells in the blood.
(unpaired) was used: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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(Figure 6B). Similarly, expansion of splenic pDCs was also
strongly reduced (Figure 6B). A minor effect was observed on
lung CD103+ DCs in the steady state, although this was indepen-
dent of FLT3L (Figure 6B). No effect was seen on DC precursor
populations in the bone marrow or peripheral tissues (Fig-
ure S4C). Together with the results shown in Figure 2, these
data indicate that splenic CD4+ and CD8+ DC development is
regulated by both p110g and p110d. They might act in a partially
redundant fashion such that one can compensate to some level
for the absence of the other.
To further characterize the signaling factors regulating organ-
specific DC development downstream of PI3K, we sought to
inhibit AKT, as the main target of PI3K-mediated signaling. We
repeated the set up described in Figure 6B using MK2206 as a
pan-Akt inhibitor. Akt inhibition impaired cDC development and
FLT3L-induced expansion in both the lung and spleen (Figure 6C)
and DC precursors in the BM and blood (Figure S4D). This is in
contrast to the liver, where DC development and expansion of
cDCs was intact (Figure 6C). Conversely Akt-inhibitor treatment
blocked the increased number of splenic pDCs (Figure 6C).
To confirm these results using a genetic approach, we then
characterized naive Akt1/ and Akt2/ mice, which are the
twomain Akt isoforms expressed in non-neuronal cells (Gonzalez
and McGraw, 2009). Akt1-deficient animals exhibited a pro-
nounced reduction in lungCD103+ DCnumbers but no difference
was observed in the CD11b+ subset (Figure 6D). Conversely,
liver-resident, as well as skin- and intestinal-resident, DCs were
unaffected by the loss of Akt1 (Figure 6D). In the spleen both
cDC subsets were reduced, although pDCs were comparable
to WT in number of cells present (Figure 6D). At the precursor
level, BM pre-DCs and lung pre-DCs were slightly affected (Fig-
ure S4E). Compared to Akt1/ animals, Akt2/ animals did
not showanydefects in theirDCcompartment (FigureS4F).Over-
all, these results demonstrate that organ-specific DC develop-
ment downstream of FLT3 is regulated at the various levels
including the PI3K-Akt pathway.
mTORC1 and mTORC2 Control DC Development in an
Organ-Specific Manner
The molecular complexes mTORC1 and mTORC2 are well-
known signaling effectors downstream of Akt, and mTORC1Figure 4. p110g Is Highly Expressed in Lung DCs and Its Function Is D
(A) Shown are the mean expression values of Pik3cg determined by microarray fo
values).
(B and C) Shown is the intracellular expression of p110g determined with flow c
Depicted are representative histograms as well as a summary of FACS data (me
(D) Naive organs of WT and Pik3cg+/KD mice were analyzed by flow cytometry; sh
(E and F) Organs of WT and Pik3cgKD/KD mice 1 day after birth were analyzed fo
summary of FACS data (mean ± SEM) of spleen and lung (F). DCs were pregate
(G) Naive BM cells of WT and Pik3cgKD/KD mice were analyzed for DC precursor p
MDPs (defined as linCD11bSca-1CD127CD115+FLT3+c-kithi cells), CDPs (d
(defined as linSca-1MHCIICD115+FLT3+CD11c+CD43intSIRPaint cells).
(H) Shown is also a summary of FACS data for the given cells (mean ± SEM).
(I) A summary of FACS data of the number of pre-DCs in spleen, liver, and lung as
pre-DCs are identified as B220loCD11c+CD43intSIRPaint, in the blood as CD11c+
(J) WTmice were lethally irradiated and reconstituted with amixture of either WT(C
ratio. After 10 weeks reconstitution, DC precursors populations in the lung and
quencies of CD45.2+ cells (mean ± SEM).
The results are representative of at least two experiments. Student’s t test (unp
Figure S2.
682 Immunity 43, 674–689, October 20, 2015 ª2015 Elsevier Inc.has been shown to regulate signaling downstream of FLT3 in
in-vitro-derivedDCs (Sathaliyawala et al., 2010) and also partially
in vivo in splenic DCs (Hackstein et al., 2003). To further address
the role of mTORC1 in FLT3 signaling and in DC development
in vivo, we administered the mTOR inhibitor rapamycin as well
as FLT3L to WT animals in a similar set up as described in Fig-
ure 6. Rapamycin treatment did not affect lung DC numbers in
the steady state nor significantly impact their expansion (Fig-
ure 7A). Similarly, no negative effect on homeostasis or FLT3L-
induced increase was observed in splenic CD8+ and liver DCs
(Figure 7A). A minor decrease in splenic CD4+ DCs was visible
with rapamycin alone, but the cells still expanded to at least
control numbers with FLT3L administration (Figure 7A). At the
precursor level, CDPs and pre-DCs in the bone marrow were
decreased in number with rapamycin alone, but this was not
observed for pre-DCs in peripheral organs (Figure S5A).
Conversely, FLT3L-mediated expansion of pre-DCs in the
spleen and to a lesser degree in the blood and lung was
decreased with Rapamycin (Figure S5A). In order to more
comprehensively address the role of the mTOR pathway in DC
development, we analyzed mice deficient in both RAPTOR and
RICTOR specifically in DCs (Kellersch and Brocker, 2013). These
two proteins are key components of mTORC1 and mTORC2,
respectively (Weber and Gutmann, 2012). Naive Itgax-CreRictor-
Raptorfl/fl mice exhibited a strong defect in the lung DC compart-
ment, as well as deficiency in splenic cDCs, in particular of the
CD8+ lineage (Figure 7B). Conversely, liver DCs as well as pDCs
in the spleen were not affected by mTOR deficiency (Figure 7B).
Thus the mTOR pathway is required for lung and splenic DC
development.
PI3Ks and Ras Are Directly Required for FLT3L-FLT3
Signaling in Lung DCs
In order to better characterize the signaling link between FLT3
and p110g in lung DCs, we sought to evaluate possible factors
linking the receptor to p110g. Ras has been described as a
potent activator of p110g (Suire et al., 2006). To test a possible
involvement of Ras in lung DC development in vivo, we analyzed
p110gDASAA/DASAA mice, which express a form of p110g lacking
all ras-binding sites that is otherwise fully intact (Suire et al.,
2006). These animals had strongly reduced numbers of lungosage Dependent
r different sorted cell populations obtained from the Immgen database (mean
ytometry (MFI) of splenic (B) and lung (C) DC subsets as well as CD19+ cells.
an ± SEM) from multiple animals.
own is a summary of FACS data of DC populations in the lung (mean ± SEM).
r their DC subsets. Shown are representative FACS dot plots (E) as well as a
d as CD45+Siglec-FMHCIIhi cells.
opulations using flow cytometry. Shown are representative dot plots depicting
efined as linCD11bSca-1CD127CD115+FLT3+c-kitlo cells), and pre-DCs
well as the frequency in blood is shown (mean ± SEM). In the spleen and liver,
FLT3+MHCII cells. See also Figure S1.
D45.1):WT(CD45.2) or WT(CD45.1):Pik3cgKD/KD (CD45.2) bonemarrow at a 1:1
bone marrow were analyzed; shown is a summary of FACS dot plots, as fre-
aired) was used: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. See also
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CD103+ DCs but were otherwise fully normal in terms of their DC
compartment in the spleen (Figure 7C). We then aimed to
demonstrate that FLT3 signaling relied directly on PI3K in lung
DCs. For this purposewe instilledWortmannin and subsequently
FLT3L intratracheally into WT animals using S6-phosphorlyation
as a readout for FLT3L-induced cell signaling. S6-P induced by
FLT3L in lung DCs in vivo was strongly inhibited by Wortmannin
treatment (Figure 7D). In conclusion, p110g is essential for FLT3
signaling in lung CD103+ DCs and to a lesser extent also in in
CD11b+ DCs, where in addition there must also be a secondma-
jor developmental pathway. Similarly, in the spleen DCs are also
PI3K dependent; however, here p110g and p110d are partially
redundant. Conversely in the liver, small intestines, and skin,
DCs are in fact independent of the PI3K-Akt-mTOR pathway
and dependent on some other signaling network downstream
of FLT3.
DISCUSSION
In this study, we described p110g as a critical intrinsic regulator
of FLT3-mediated lung DC development. We demonstrated
that the function of p110g was lung specific and gene dosage
dependent, conferring an organ-specific layer of regulation for
responding to the master cytokine FLT3L. We showed that this
signaling is part of a lung-specific signaling axis going through
the FLT3-Ras-p110g-Akt-mTOR pathway to regulate DC devel-
opment. Furthermore, we demonstrated that the signaling fac-
tors downstream of FLT3 required for development of DC
populations in other peripheral tissues such as the spleen and
liver were also organ and subset specific. TFs such as NOTCH2
(Lewis et al., 2011) and IRF4 (Schlitzer et al., 2013) have been
previously implicated to be important for specific DC subsets
in particular organs, but to date nothing has been known about
tissue-specific signaling networks in DC subsets. Our experi-
ments revealed that lung CD103+ DCs were particularly strongly
affected by loss of p110g signaling, correlating with high p110g
mRNA and protein expression levels in these cells. The strong
dependence of lung CD103+ DCs on p110g can also partially
be explained by the strict requirement for intact FLT3 signaling
for the generation of these cells in general (Schlitzer et al.,
2013). Furthermore, the lung has been shown to have particularly
high levels of FLT3L in the steady state (Miloud et al., 2012), sug-
gesting an important role of FLT3L in regulation of lung immune-
homeostasis. The fact that lung CD11b+ conventional DCs were
considerably less affected than the CD103+ subset by the loss
of p110g kinase function as well as PI3K and Akt blocking in ho-
meostasis is possibly due to the fact that they are less dependentFigure 5. p110g Controls Lung DC Development Downstream of FLT3
(A andB)WT,Pik3cgKD/KD, andPik3cg/micewere injected subcutaneously daily
cytometry. Values shown are means ± SEM of groups of DC subsets in the lung
(C) WTmice were lethally irradiated and reconstituted with amixture of either WT:B
transfer, micewere treated daily with PBS or 10 mg FLT3L subcutaneously for 8 day
Values shown are means ± SEM of groups of indicated mice.
(D) Shown are representative histograms of FLT3 surface expression of lung DC
(E) Shown are representative histogram overlays of FLT3 surface expression of lun
(F) Lungs and spleens of naive Flt3+/+, Flt3+/, and Flt3/mice were analyzed by
The data are representative of two experiments.
(G) FLT3 surface expression in Flt3+/+, Flt3+/, and Flt3/ mice. Shown are repre
Student’s t test (unpaired) was used: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0
684 Immunity 43, 674–689, October 20, 2015 ª2015 Elsevier Inc.on FLT3 for their development in general than cells of the CD103+
DC lineage. This is evident in the literature (Schlitzer et al., 2013)
and also from our experiments, where Flt3/ mice had only a
moderate reduction in these cells. These results suggest the ex-
istence of an unknown additional major pathway controlling the
development of these cells in the lungs and in other tissues apart
from FLT3, as depicted in the scheme in Figure 7E. Furthermore,
the differential localization of CD103+ DCs and CD11b+ DCs in
the lung (Sung et al., 2006) might explain the differing develop-
mental dependence on FLT3L. CD103+ DCs are mainly found
in the epithelial lining and the perivasculature whereas CD11b+
DCs are located more in the lung parenchyme. Interestingly,
epithelial and endothelial cells were shown to be the main pro-
ducers of FLT3L in the lung tissue (Miloud et al., 2012), suggest-
ing a close proximity of lung CD103+ DCs to FLT3L-secreting
epithelial cells in situ.
Lymphoid DCs were shown to depend less on FLT3 (Waskow
et al., 2008) and were thus less affected by PI3K and Akt inhibi-
tion in the steady state. Whether lymphoid and CD11b+ DCs in
NLTs share an additional major developmental pathway remains
to be addressed. Only when the FLT3-FLT3L system in splenic
DCs was pushed with exogenously administering FLT3L was a
pronounced deficiency revealed if PI3Ks and Akt are blocked.
We showed that splenic DCs depended on both p110g and
p110d for responding to FLT3L and that there was a partially
redundant function of these two PI3K subunits. More specif-
ically, CD8+ DCs seemed to depend more strongly on p110d,
whereas CD4+ DCs depended more on a non-kinase domain
of p110g. These results are somewhat surprising because the
importance of p110g in CD4+ DCs contrasts with a complete
redundancy of this protein in SI CD103+CD11b+DCs. These cells
depend on similar TFs such as NOTCH2 and LTbR (Merad et al.,
2013). Probably, this discrepancy can be explained by the tis-
sue-specific adaptation of each subset leading to differential
gene expression patterns (Miller et al., 2012) and thus tissue-
specific functionality. In addition, examining the results obtained
with the DC-specific Rictor/Raptor deficiency, it is evident that
the mTOR pathway in general plays a crucial role in lung and
splenic DC development. Rapamycin administration did not,
however, affect DC homeostasis, suggesting either a more
important role of mTORC2 rather than mTORC1 or a complete
redundancy between the mTOR complexes. Overall, these re-
sults point toward a similar signaling wiring of splenic and lung
DCs for responding to FLT3L. Both depended on the PI3K-Akt-
mTOR pathway and tissue specificity is achieved at the level of
the PI3K subunit employed in FLT3 signaling. Interestingly,
global kinase deficiency of p110g led to a decreased numberfor 8 days with 10 mg of FLT3L and organswere subsequently analyzed by flow
and spleen of indicated mice. The data are representative of two experiments.
atf3/ orPik3cgKD/KD:Batf3 / bonemarrow at a 1:5 ratio. 10 weeks after BM
s. On day 9,micewere sacrificed and organswere analyzed by flow cytometry.
subsets as well as CD19+ B cells as determined by flow cytometry.
g DC subsets fromWT and Pik3cgKD/KDmice as determined by flow cytometry.
flow cytometry. Values shown are means ± SEM of lung and liver DC subsets.
sentative histograms of selected DC subsets from the spleen, lung, and liver.
.0001. See also Figure S3.
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Figure 7. Ras and mTOR Are Required for Lung DC Development
(A) WT mice were injected subcutaneously daily for 8 days with 10 mg of FLT3L or PBS as well as 0.5 mg/kg rapamycin or PBS i.p. at the same time and organs
were subsequently analyzed on day 9 by flow cytometry. Values shown are means ± SEM of DC subsets in indicated organs (n = 4–5 mice/group).
(B) Organs of naive Cd11c-CreRictor-Raptorfl/fl and Rictor-Raptorfl/fl mice were analyzed with flow cytometry. Values shown are means ± SEM of DC subsets in
indicated organs (n = 4 mice/group).
(C) Organs of naive WT and Pik3cgDASAA/DASAA mice were analyzed by flow cytometry. Values shown are means ± SEM of DC subsets in indicated organs (n =
3–4 mice/group).
(D) WTmice were treated with FLT3L (1 mg) and with or without Wortmannin (1.2 mg/kg) 15 and 30 min, respectively, prior analysis of S6-phosphorylation by flow
cytometry. Depicted are histogram overlays of lung DC subsets including MFI.
Student’s t test (unpaired) was used: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. See also Figure S5.of lymphoid CD8+ DCs, but no intrinsic developmental role could
be found with the mixed bone marrow chimeras, suggesting the
existence of an additional p110g-dependent extrinsic mecha-Figure 6. DC Subsets Show Organ- and Subset-Specific Requirement
(A–C) WT mice were injected subcutaneously daily for 8 days with 10 mg of FLT3L
(B) 15 mg/kg IC87114, a PI3Kd inhibitor, or (C) 15 mg/kg MK2206, an Akt inhibito
Values shown are means ± SEM of DC subsets in indicated organs of groups of
(D) Organs of naive WT and Akt1/mice were analyzed by flow cytometry. Value
(n = 4–5 mice/group). The results are representative of at least two experiments.
Student’s t test (unpaired) was used: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0
686 Immunity 43, 674–689, October 20, 2015 ª2015 Elsevier Inc.nism regulating CD8+ DC development. The PI3K-Akt-mTOR
pathway appeared to be completely redundant for development
of liver and SI LP DCs. This implies that another main signalings for PI3Ks and Akt for Their Development
together with intraperitoneal (A) 1.2 mg/kg Wortmannin, a pan-PI3K inhibitor,
r. Indicated organs were subsequently analyzed on day 9 by flow cytometry.
mice (n = 4–5 mice/group).
s shown are means ± SEM of DC subsets in indicated organs of groups of mice
.0001. See also Figure S4.
pathway must regulate signaling downstream of FLT3 in these
cells, such as the MAPK-Erk pathway, which has been demon-
strated to be activated by FLT3 (Scheffler et al., 2014) and is
also target of Ras (Cseh et al., 2014). Interestingly, tissue-resi-
dent pre-DCs had already acquired an organ-specific signature
to a certain degree, as lung pre-DCs partially depended on
p110g, whereas this was not the case for pre-DCs in the BM.
Whether these differing dependencies reflect differential devel-
opmental origin or are dictated by tissue-specific factors remain
to be addressed.
Furthermore, we showed that regulation of FLT3 responsive-
ness at the level of PI3Ks is not specific to the cDC lineage but
also applies to pDCs. These cells depended generally on PI3K
signaling in the steady state as well as specifically on p110d
for responding to FLT3L, which correlated well with the high
expression of this protein in splenic pDCs. Whether pDCs also
acquire a tissue-specific signature in relation to FLT3 respon-
siveness needs to be examined in future experiments. FLT3
has been shown to regulate DC homeostasis in LTs by driving
both differentiation and proliferation of pre-DCs as well as cell
division of mature cells in situ (Liu et al., 2009). In the lung we
showed with genetic and inhibitor approaches that p110g
controlled lung CD103+ and CD11b+ DC proliferation. Further-
more, lung-resident pre-DCs were also partially dependent on
PI3Ks for expansion, suggesting that FLT3 controls DC genera-
tion in the lung at multiple levels and in a similar manner to LTs.
Taken together, the results presented in this paper suggest a
layer of regulation downstream of the common and well-estab-
lished cellular DC differentiation signal FLT3L. This differential
control of FLT3 signaling conferred tissue and subset specificity
to mature DCs and also, to a degree, to their immediate organ-
resident precursors, thereby contributing to the generation of
a wide and highly adapted set of sentinel cells. p110g was
shown to be crucial for FLT3-mediated lung CD103+ DC devel-
opment and thus serves as a prime example of such a tissue-
and subset-specificity-generating molecule. Future endeavors
must address the underlying reasons for the organ-specific
signaling bias in DC subsets and what factors control the gener-
ation as well as possible plasticity and adaptation in response to
inflammation.EXPERIMENTAL PROCEDURES
Mice
C57BL/6 mice were either bred in-house or purchased from Charles River.
Pik3cg/ and Pik3cgKD/KD mice backcrossed on C57BL/6 for 20 and 15 gen-
erations, respectively, were provided by E. Hirsch (University of Torino).
Batf3/ mice were obtained from Jackson. Flt3/ mice were provided by
A. Rolink (University of Basel). Pik3cgDASAA/DASAA mice were provided by
L. Stephens (Babraham Institute). Akt1/ and Akt2/ mice were provided
by O. Tschopp (University of Zu¨rich). ItgaxRictor-Raptorfl/fl mice were provided
by T. Broker (Kellersch and Brocker, 2013). All animals were housed in individ-
ually ventilated cages under specific-pathogen-free conditions at the ETH
Phenomics Facility and used for experiments at between 6 and 14 weeks of
age unless otherwise stated. All animal experiments were performed accord-
ing to institutional guidelines and Swiss regulations and had been approved by
responsible animal ethics committees.
Cell Suspension Preparations
Mice were sacrificed by an overdose of sodium pentobarbital by i.p. injection.
Organs were removed and then processed according to the following proce-dure. Spleens, thymi, lymph nodes, liver, and kidney were minced and then
digested with 2 mg/ml of type IV collagenase (Worthington) and 0.02 mg/ml
DNaseI (Sigma) at 37C for 45 min and subsequently passed through a
70 mm cell strainer. Leukocytes from the liver and kidney were isolated by Per-
coll gradient centrifugation (GEHealthcare). Lungs were digested with 1mg/ml
Hyaluronidase (Sigma), 25mg/mlCollagenase XI (Sigma), 50mg/ml LiberaseTM
(Roche), and 0.02 mg/ml DNaseI (Sigma) at 37C for 45 min and subsequently
passed througha70mmcell strainer. Small intestineswere treatedasdescribed
(Bogunovic et al., 2009). ACKbufferwasused for erythrocyte lysis for all organs.
Bonemarrowcellswere flushed from femurs and tibia and then useddirectly for
staining. In the case where total numbers are shown, it is always the combined
number of one tibia and one femur. For experiments where phosphoproteins
were stained by flow cytometry, tissues were not digested but directly minced
and smashed through a cell strainer for further processing according to the
phospho-specific antibody manufacturer’s instructions.
Flow Cytometry
Multiparameter analysis was performed on a FACSCanto II or LSR Fortessa
(BD) and analyzed with FlowJo software (Tree Star). Antibodies and reagents
used are listed in Supplemental Experimental Procedures.
Bone Marrow Chimeras
For bone marrow chimeras, C57BL/6 CD45.2+ mice were lethally irradiated
(9.5 Gy, using a caesium source) and reconstituted with 5–10 3 106 BM cells
of the background and with the ratio indicated for each experiment. Mice were
analyzed 9 weeks after reconstitution.
FLT3L and Inhibitor Administration
Mice were injected daily with 10 mg recombinant mouse FLT3L (homemade)
subcutaneously for 8 days and tissues were analyzed on day 9. In some ex-
periments signaling molecule inhibitors were administered intraperitoneally
at the same time. The following inhibitors were used in these experiments:
15 mg/kg MK2206 (Selleckchemicals) for p-akt; 15 mg/kg IC87114 for p110d
(Selleckchemicals); 0.5 mg/kg Rapamycin (LubioScience) for mTORC1; and
1.2 mg/kg Wortmannin (Sigma) for PI3Ks.
BrdU Incorporation
Mice were injected with 1 mg BrdU (BD-PharMingen) and sacrificed 2 hr later.
Tissues were harvested and prepared according to the procedures above and
stained with the BrdU Flow Kit (BD-PharMingen) according to the manufac-
turer’s instructions.
EdU Incorporation
Mice were injected with 0.5 mg EdU (Life Technologies) and mice were sacri-
ficed after overnight incorporation. Tissues were harvested and then treated
according to the manufacturer’s instructions using the Click-iT Alexa Fluor
488 Imaging Kit (Life Technologies).
Statistical Analysis
Mean values, SD, SEM, and Student’s t test (unpaired) were calculated with
Prism (GraphPad Software). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.immuni.2015.09.006.
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